title: Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.
abstract: High-grade (World Health Organization [WHO] Grade II and III) meningiomas constitute a minority of all meningioma cases but are associated with significant morbidity and mortality, due to more aggressive tumor behavior and a tendency to recur despite standard therapy with resection and radiotherapy. They display a higher degree of vascularity than WHO Grade I meningiomas and produce angiogenic and growth factors, including vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF-A, has been used in the treatment of recurrent or progressive meningiomas resistant to standard therapy. We report a patient with a recurrent left frontotemporal meningioma and associated-vision loss who experienced substantial visual field recovery after 3 cycles of bevacizumab. In addition, we provide a review of the literature regarding the efficacy of bevacizumab in the treatment of recurrent meningiomas.
authors.affiliation: Departments of Neurology (KIL, MMM), Neurosurgery (RCR), and Radiation Oncology (JKR), University of Washington, Seattle, Washington; and Neuro-Ophthalmic Consultants Northwest (SRH), Swedish Medical Center, Seattle, Washington.
authors.forename: K Ina
authors.initials: KI
authors.lastname: Ly
authors.forename: Steven R
authors.initials: SR
authors.lastname: Hamilton
authors.forename: Robert C
authors.initials: RC
authors.lastname: Rostomily
authors.forename: Jason K
authors.initials: JK
authors.lastname: Rockhill
authors.forename: Maciej M
authors.initials: MM
authors.lastname: Mrugala
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000068258:Bevacizumab / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D008579:Meningioma / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D010468:Perceptual Disorders / Q000139:chemically induced*; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab